• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcturus Therapeutics Holdings Inc (NQ: ARCT )

    20.61 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 17
    Open 20.61
    Bid (Size) 20.61 (1)
    Ask (Size) 21.25 (14)
    Prev. Close 20.61
    Today's Range 20.61 - 20.61
    52wk Range 17.52 - 45.00
    Shares Outstanding 26,562,951
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
    From Arcturus Therapeutics
    Via Business Wire

    Performance

    YTD
    -37.72%
    -37.72%
    1 Month
    -6.28%
    -6.28%
    3 Month
    -24.59%
    -24.59%
    6 Month
    -40.76%
    -40.76%
    1 Year
    -21.49%
    -21.49%

    More News

    Read More
    Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
    Via Benzinga
    Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
    Via Benzinga
    Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
    Via Benzinga
    Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
    Via Benzinga
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
    From Arcturus Therapeutics
    Via Business Wire
    Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
    Via Benzinga
    ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.